Introduction
Inhibition of the renin-angiotensin-aldosterone system (RAAS) either via ACE-inhibition, or more recently via the use of angiotensin II receptor antagonists (AIIAs), has become an important therapeutic tool for the treatment of hypertension and its cardiovascular sequelae. Basic scientific investigation of the pathophysiology of cardiovascular disease has revealed many compelling reasons why inhibition of the RAAS might confer added value, over and above the benefits of blood pressure reduction alone.These include the haemodynamic actions of angiotensin II (Ang II) on the systemic circulation and microvascular circulations, along with many potentially deleterious nonhaemodynamic actions of Ang II. 1 Amongst these are the cell growth promoting actions of Ang II on vascular smooth muscle and cardiac myocytes, 2,3 the pro-inflammatory and pro-fibrotic potential of Ang II, 4, 5 and its capacity to induce oxidant stress and endothelial dysfunction, [6] [7] [8] the pro-atherogenic actions of Ang II, 9 its potential to stimulate microvascular growth 10 and the recent studies implicating Ang II in the pathogenesis of atherosclerotic plaque instability. 11 Allied to this wealth of laboratory-derived data is a large body of clinical trial evidence supporting a role for the RAAS in the pathogenesis of cardiovascular disease. ACEinhibition has been shown to improve survival in patients with heart failure due to impaired systolic function 12 and in patients post-myocardial infarction. 13 ACE-inhibition has also been shown to reduce the progression of diabetic nephropathy 14, 15 and possibly retinopathy 10, 16 and to regress left ventricular hypertrophy. More recently, in the CAPPP 17 and STOP-2 18 studies, ACE-inhibition was shown to be as effective as other antihypertensive therapies at reducing cardiovascular morbidity and mortality in hypertensive patients. Important questions remain. How much of the effect of RAAS inhibition can be attributed to blood pressure reduction and how much of the effect, if any, can be attributed to benefits independent of blood pressure reduction? The answer to this question would be decisive in defining whether RAAS inhibition is merely another means of inducing the benefits associated with blood pressure reduction per se in hypertensive people, or whether RAAS inhibition should be considered an adjunctive therapy for all patients at risk of cardiovascular disease (hypertensive or not), in much the same way as aspirin and statins are targeted at patients at high cardiovascular risk. The recently reported Heart Outcomes Prevention Evaluation (HOPE) study 19 was designed to test the hypothesis that ACE-inhibition with ramipril improves the cardiovascular outcome of patients at high cardiovascular risk.
The HOPE study
This study was conducted in 19 countries in North and South America and in Europe. 19 A total of 9297 patients, aged 55 years or older, were randomly assigned to treatment with either ramipril (10 mg/day) or matching placebo for five years. The patients were deemed to be at high risk for cardiovascular disease by virtue of a prior history of coronary heart disease, stroke, peripheral vascular disease or diabetes, plus at least one other cardiovascular risk factor (hypertension, elevated total cholesterol level, reduced high density lipoprotein (HDL) cholesterol level, cigarette smoking or microalbuminuria). Patients with known heart failure or poor systolic function were excluded. Some of the patients also received the antioxidant vitamin E in a 2 x 2 factorial design. The impact of vitamin E was disappointing and will not be considered further in this discussion. The mean age of the study population was 66 years and a majority were men (about 75%). A majority also had a prior history of coronary heart disease (about 80%), over 40% had evidence of peripheral vascular disease and 11% had a history of stroke or transient cerebral ischaemia. Almost 40% were diabetic (>90% type 2 diabetes) and almost 50% had hypertension. Remarkably, the definition of "hypertension" was not specified in the main publication 19 but review of another publication from the HOPE study investigators 20 confirms that it was defined as "the taking of drugs to treat hypertension, or blood pressure at recruitment >160 mmHg systolic or >90 mmHg diastolic."
The primary outcome of the study was a composite of myocardial infarction, stroke or death from cardiovascular causes. Secondary outcomes included death from any cause, the need for revascularisation, hospitalisation for unstable angina or heart failure and complications related to diabetes.
Compliance with therapy throughout the study was good but by the end of the study, 28.9% had permanently discontinued ramipril and 27.3% had permanently discontinued placebo.The main reason for discontinuation of the ACE-inhibitor was cough in 7.3% of patients (1.8% with placebo). A total of 651 patients assigned to ramipril reached the primary endpoint (14%) compared with 826 (17.8%) assigned to placebo (p<0.001), which represents a significant risk reduction of 22% in favour of ramipril ( Figure 1 ). Compared with placebo, treatment with ramipril also reduced the rate of death from cardiovascular causes by 26% (p<0.001), reduced myocardial infarction by 20% (p<0.001), stroke by 32% (p<0.001) and death from any cause by 16% (p<0.005). Sub-group analyses suggested that the beneficial effects of ramipril on the primary outcome were consistent in those with or without diabetes, hypertension or microalbuminuria and in younger (<65 years) versus older (>65 years) patients.
Diabetes; HOPE and MICRO-HOPE
A detailed analysis was also performed and reported on the large cohort of diabetic patients recruited into the HOPE study. 20 In all, 3654 people with diabetes were randomised into the study (39.3% of the HOPE study population). Of these, 98% were defined as type 2 diabetics of whom approximately 20% required dietary therapy alone, about 25% received insulin alone and about half received oral hypoglycaemic agents. These patients had at least one other cardiovascular risk factor in addition to their diabetes. In addition to the main exclusion criteria specified above, diabetic patients with overt nephropathy (dip-stick positive proteinuria), any other severe renal disease, hyperkalaemia or uncontrolled hypertension were excluded. There were more women (about onethird) than in the main study and more of the diabetic patients were defined as "hypertensive" at baseline. As part of the diabetic cohort study, microalbuminuria was measured as a urinary albumin creatinine ratio (ACR) at baseline in 98% of the patients and in 86% at the end of the study. Data was also collected on the need for laser therapy for retinopathy.This preplanned sub-study was referred to as the MICRO-HOPE study 20 and set out to define whether ramipril delayed the onset of microalbuminuria, overt nephropathy and microvascular complications in the diabetic cohort.
In the diabetic cohort, ramipril lowered the risk of the composite primary endpoint by 25% (p<0.0004) versus placebo. 20 This finding is consistent with the benefits observed in the study overall. 19 Also of interest, the event rates in the diabetic patients receiving placebo were very similar to those observed in the non-diabetic patients receiving placebo (19.8% versus 17.8%). This observation is consistent with the notion that diabetes is a vascular disease 21 and that diabetic patients should be perceived and managed as patients at high cardiovascular risk. All other risk reductions for the pre-specified secondary endpoints were similar to those observed in the main study.
In the MICRO-HOPE study, 10% of patients developed an elevated ACR indicative of nephropathy, 7% on ramipril and 8% on placebo (p<0.027).When 24-hour urine estimations of protein excretion were examined to provide a more stringent definition of nephropathy, 6% on ramipril and 7% on placebo were affected, which just failed to reach significance (p<0.07). In patients without baseline microalbuminuria, the risk of new microalbuminuria was non-significantly reduced by 9% (p<0.17). Ramipril reduced the risk of combined microvascular endpoints (overt nephropathy, dialysis, laser therapy) by 16%, (p<0.036).
Conclusions from the HOPE and MICRO-HOPE studies
The HOPE study was an impressive and well conducted study that addressed an important clinical question. Its results have already begun to have a significant impact on clinical practice and it will no doubt be regarded a "landmark study" in years to come. What messages can we take away from this study? How reliable and definitive are the study's conclusions? What are the mechanisms underlying the benefits of ramipril in this study?
The authors conclude that blockade of the RAAS with ramipril is beneficial in a broad range of patients at high risk of cardiovascular disease, including those with diabetes, when compared with placebo. 19, 20 This is a sound conclusion. The study demonstrates unequivocal benefit of active treatment. An important distinction for this study is that these patients were already receiving a range of conventional therapies to reduce their cardiovascular risk and were reported to be normotensive, thus, under normal circumstances they would not necessarily have received additional ACE-inhibition. The authors also conclude that ACE-inhibition could now be regarded as a suitable preventive strategy for patients at high risk of cardiovascular disease and this too is supported by their data.There are, however, some aspects of their conclusions which, in my view, are less wellfounded. The impact of blood pressure reduction versus blockade of the RAAS The authors and the study sponsors have been particularly dismissive of the potential impact of the blood pressure lowering action of ramipril as an explanation for their findings and, instead, have readily embraced the concept of a unique, blood pressure-independent, cardiovascular-protective effect of ramipril. As highlighted earlier, there are many reasons why inhibition of the RAAS might be expected to provide "added value" in the management of cardiovascular disease risk. Nevertheless, to conclude that the majority of the benefits of ramipril in the HOPE study are independent of its "extremely small" effect on blood pressure 19 was a blinkered assessment of the data. This is perhaps exemplified by the fact that there was no definition of hypertension in the main study report and scant information about the methods of blood pressure measurement. When was blood pressure measured? How often and by whom? How complete and consistent is the blood pressure data? There was no data about the blood pressure changes in the hypertensive patients versus the normotensive patients, nor are the standard deviations of the blood pressure change on therapy reported. These may seem to be minor details but they are important in the context of a study of a licensed antihypertensive agent being used versus placebo in a clinical trial. Is it reasonable to conclude that the "extremely small" blood pressure reductions reported in the ramipril-treated patients are insignificant? Ramipril, an ACE-inhibitor licensed for the treatment of hypertension, was administered at 10 mg per day, the maximum recommended dose for the treatment of hypertension! When compared with patients receiving placebo, ramipril at this dose would be expected to reduce systemic blood pressure, particularly when one considers that 15-20% of the patients were already receiving diuretics and 40-50% were receiving calcium channel blockers, both of which are well-recognised to potentiate the blood pressure lowering action of ACE-inhibition. The reported placebo-adjusted mean fall in blood pressure due in patients assigned to ramipril in the whole study was 3/2 mmHg 19 and was 2.2/1.4 mmHg in the diabetic cohort. 20 The true significance of this magnitude of blood pressure reduction in patients at high cardiovascular risk is difficult to define because there have been no previous studies in which blood pressure has been actively lowered within the "normal range" in a high risk population. Nevertheless, this does not mean its impact can be dismissed. A recent re-analysis of the Framingham data suggests that the risks previously attributed to hypertension have been underestimated. 22 Although the patients included in the HOPE study were considered to be "normotensive" by conventional criteria, it is well recognised that blood pressure is a continuous risk variable and the threshold for defining hypertension is arbritrary. Moreover, it is well recognised that the "cardiovascular risk potency" of any level of blood pressure is magnified by the co-existence of other risk factors or pre-existing cardiovascular disease. 23 This is particularly true in diabetic patients who appear to be especially vulnerable to hypertensive injury. 24, 25 The HOPE study patients were selected on the basis of pre-existing cardiovascular disease or diabetes and the presence of at least one other risk factor. Thus, by design, the study selected patients in whom blood pressure reduction, however small, would be expected to have more impact. In support of this concept, the Hypertension Optimal Treatment (HOT) study 26 revealed continuous benefit when blood pressures were reduced within the conventional normal range (i.e. diastolic blood pressures <90 mmHg -<80 mmHg) in two groups of patients in particular: patients with pre-existing ischaemic heart disease and diabetic patients. Moreover, seemingly small reductions in blood pressure within this normal range were associated with substantial reductions in cardiovascular morbidity and mortality, especially in the diabetic patients. 26 Indeed this data led to the decision of other national guideline authors to advocate more aggressive blood pressure lowering and targets in diabetic patients. 27, 28 It is worth further considering the potential impact of blood pressure reduction based on the results of previous clinical trials.The Syst-Eur study of isolated systolic hypertension in the elderly (mean age 70 years) contained a cohort of diabetic patients (492; 11.5%) 29 at similar cardiovascular risk to those recruited into the HOPE study. The pretreatment blood pressures were a mean of 175/85 mmHg and the placebo-adjusted fall in blood pressure after a median of two years antihypertensive therapy (nitrendipine ± enalapril ± thiazide) was 8.6/3.9 mmHg.The effect of antihypertensive therapy on cardiovascular endpoints and Table 1 Comparison of % cardiovascular disease (CVD) risk reduction in the HOPE study 19 and the Syst-Eur (diabetes cohort) study 29 at two years, expressed per mmHg reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP). mortality in the Syst-Eur diabetic sub-study was dramatic. 29 A composite of cardiovascular endpoints was reduced by 69%, cardiovascular death by 76% and all-cause mortality by a massive 55%. The reduction in the risk of the primary endpoint in Syst-Eur per mmHg reduction in systolic blood pressure was 8% (69% ÷ 8.4) and per mmHg diastolic blood pressure was 17.7% (69% ÷ 3.9). The temporal trends reported for HOPE after a similar time period of study of two years reveals a risk reduction of 18% for the primary composite endpoint. 19 At the two year time point, the blood pressure difference between ramipril and placebo was reported to be 3/2 mmHg. 19 In HOPE after a time interval of two years, the reduction in the risk of the primary endpoint was therefore 6% per mmHg systolic blood pressure reduction (18 ÷ 3) and 9% per mmHg diastolic blood pressure reduction (18 ÷ 2) .This simple analysis (Table 1 ) reveals the true power of seemingly trivial blood pressure reductions to influence cardiovascular event rates in high risk populations such as those studied in HOPE. It also reveals that at least equivalent benefit was seen in the Syst-Eur diabetes sub-study, which suggests that a majority, if not all of the benefits of ramipril observed in HOPE could have been due to blood pressure reduction. Cross study analyses such as these are not ideal but this Syst-Eur diabetic population was of similar age and risk to the high risk HOPE study population and published data on equivalent time points (two years) are available to conduct the analysis. It is therefore somewhat surprising that the Syst-Eur diabetes sub-study was not referred to in the HOPE publications. It was perhaps a more relevant comparator (active treatment versus placebo in high risk patients) than the United Kingdom Prospective Diabetes study (UKPDS) 30 and the CAPPP study 17 (active treatment versus active treatment).
EDITORIAL REVIEW
The aforementioned examples suggest that it would be inappropriate to dismiss the "extremely small" blood pressure lowering effect of ramipril in the HOPE study as being unimportant. It may well have been the major determinant of the beneficial effects of ramipril in the HOPE study, and may thus be reproduced by other classes of drugs that induce a similar fall in blood pressure.
Conclusions
The HOPE study has provided important new data with regard to cardiovascular protection for patients at high risk of cardiovascular disease. Its results demonstrate that ACE-inhibition and the associated blood pressure reduction are unequivocally beneficial in high risk patients and any strategy that imparts benefit in a high risk group, whatever the mechanism, should be deployed. Nevertheless, the pathophysiological basis for this benefit is not unimportant. If there is a benefit that is independent of blood pressure reduction, related to blockade of the RAAS or potentiation of bradykinin by ACE-inhibition, then this represents a key advance and should prompt further study into the pathophysiological basis of this effect in order that it may be optimised. It also raises important questions.For instance,what is the dose of ACE-inhibition required for maximal benefit? Is bradykinin important in this response? If so, would the benefit be reproduced by angiotensin II receptor antagonists?
In contrast, if the benefit observed in the HOPE study is largely related to systemic blood pressure reduction, it questions the validity of the concept of "normotension" in patients at high risk of cardiovascular disease. It would also pose the question as to whether blood pressure thresholds for intervention with drug therapy and targets on therapy should be lowered beyond current guidance for patients at high cardiovascular risk.
The HOPE study results were heralded by much hype in the lay press and have been followed by an almost evangelical embracing of the RAAS hypothesis. In today's clinical research environment this has become inevitable, but should not replace the need for objective appraisal of the data and their scientific and clinical implications. I strongly support the view that inappropriate activation of the RAAS and other neurohumoral mediators contributes to premature cardiovascular morbidity and mortality, and that blockade of the RAAS will most likely provide cardiovascular benefits beyond blood pressure reduction. However, when clinical studies, such as HOPE, are designed in which an RAAS blocking agent challenges placebo, some blood pressure reduction is inevitable. It may seem trivial but in high risk patients, over a long duration of study, its impact cannot be considered less relevant or less important than the non-haemodynamic actions of RAAS blockade.The mechanism of benefit of ramipril in the HOPE study is unresolved. Nevertheless, this important study has broadened the spectrum of cardiovascular diseases amenable to intervention by blockade of the RAAS. In so doing the hype may be justified in that it offers high risk patients improved hope of prolonged survival, whatever the mechanism. The clinical pragmatist might rightly conclude that is enough.
